GlassScriptPhysician profile
Ushaben V Patel
NPI 1962740886
$1,183.20
in general payments reported to CMS, 2019-2025
20 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $355 · 2023: $261 · 2024: $189 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $195.28 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.24 | 2021-2022 | |
| Dexcom, INC. | $140.60 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $109.08 | 2021-2022 | |
| Abbvie INC. | $96.12 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $94.31 | 2023-2024 | Verquvo, Belsomra, Steglatro |
| Xeris Pharmaceuticals, INC. | $69.20 | 2022-2024 | Gvoke Hypopen |
| Novo Nordisk INC | $57.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $51.62 | 2022-2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $37.31 | 2025 | Airsupra, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.21 | 2021 | |
| Boston Scientific Corporation | $24.80 | 2023 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $23.25 | 2025 | Evkeeza |
| Alkermes, INC. | $22.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.17 | 2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $16.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.49 | 2021 | |
| Phadia US INC. | $14.44 | 2022 | |
| Abbott Laboratories | $13.76 | 2023 | Freestyle Libre 3 |
| Genentech USA, INC. | $10.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ushaben Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.